Pluri Inc. - Asset Resilience Ratio
Pluri Inc. (PLUR) has an Asset Resilience Ratio of 22.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Pluri Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Pluri Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PLUR current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Pluri Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PLUR total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.90 Million | 22.65% |
| Total Liquid Assets | $5.90 Million | 22.65% |
Asset Resilience Insights
- Good Liquidity Position: Pluri Inc. maintains a healthy 22.65% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Pluri Inc. Industry Peers by Asset Resilience Ratio
Compare Pluri Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Pluri Inc. (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Pluri Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 38.05% | $14.72 Million | $38.68 Million | -20.65pp |
| 2024-06-30 | 58.70% | $23.20 Million | $39.53 Million | -9.83pp |
| 2023-06-30 | 68.53% | $34.81 Million | $50.80 Million | +2.06pp |
| 2022-06-30 | 66.47% | $45.24 Million | $68.06 Million | +30.43pp |
| 2021-06-30 | 36.04% | $33.71 Million | $93.54 Million | -21.21pp |
| 2020-06-30 | 57.25% | $37.51 Million | $65.53 Million | -5.35pp |
| 2019-06-30 | 62.60% | $19.60 Million | $31.31 Million | +8.49pp |
| 2018-06-30 | 54.10% | $21.08 Million | $38.96 Million | -2.91pp |
| 2017-06-30 | 57.01% | $21.40 Million | $37.53 Million | +0.45pp |
| 2016-06-30 | 56.56% | $25.98 Million | $45.94 Million | +13.40pp |
| 2015-06-30 | 43.16% | $29.42 Million | $68.16 Million | -23.59pp |
| 2014-06-30 | 66.75% | $49.41 Million | $74.02 Million | +1.04pp |
| 2013-06-30 | 65.71% | $44.89 Million | $68.32 Million | +50.90pp |
| 2012-06-30 | 14.81% | $7.02 Million | $47.42 Million | -10.13pp |
| 2009-06-30 | 24.94% | $1.11 Million | $4.46 Million | -8.13pp |
| 2008-06-30 | 33.06% | $1.19 Million | $3.58 Million | -22.81pp |
| 2007-06-30 | 55.87% | $3.76 Million | $6.73 Million | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more